Governance & Derivative

ImmunityBio, Inc. (NasdaqGS: IBRX)

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX).

On May 11, 2023, the Company disclosed that it had received a complete response letter (“CRL”) from the FDA stating that, among other things, it could not approve the company’s Biologics License Application (“BLA”) for its flagship product candidate, an antibody called N-803, known internally as Anktiva, due to deficient manufacturing practices.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws. Specifically, the suit alleges that, in the course of seeking FDA approval for Anktiva, the Company misled investors into believing that Anktiva was manufactured in compliance with industry standards. Recently, the court presiding over that case denied the Company’s motion to dismiss in part, allowing the case to move forward.

KSF’s investigation is focusing on whether ImmunityBio’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of ImmunityBio shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (, or fill out the form on this page.